Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial
暂无分享,去创建一个
G. Dangas | Haichang Wang | Jing Li | B. Xu | C. Guan | Yuejin Yang | Kai Xu | Quanmin Jing | Yaling Han | Xueqi Li | Xianxian Zhao | Xuebin Cao | Q. Zheng | Jun Zhang | Zhifang Wang | Xuezhong Zhao | Xiaoyan Li | Pengfei Yu | Hong-yun Zang | Wenyue Pang | Xue-Ling Li | Xue-bin Cao | K. Xu | Bo Xu | Xueqi Li
[1] Giuseppe Biondi-Zoccai,et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.
[2] Walter Desmet,et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.
[3] Samin K. Sharma,et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.
[4] Deepak L. Bhatt,et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. , 2015, Journal of the American College of Cardiology.
[5] J. Wójcik,et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. , 2015, Journal of the American College of Cardiology.
[6] W. Weaver,et al. Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement , 2015, Circulation.
[7] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[8] A. Kirtane,et al. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents. , 2014, JACC. Cardiovascular interventions.
[9] Antonio Colombo,et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.
[10] E. Vicaut,et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.
[11] F. Jaffer,et al. Stent thrombosis: a clinical perspective. , 2014, JACC. Cardiovascular interventions.
[12] Helmut Baumgartner,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[13] M. Jeong,et al. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.
[14] Deepak L. Bhatt,et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.
[15] Laura Mauri,et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[16] Y. Jang,et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.
[17] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[18] J. Marchesini,et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.
[19] M. Jeong,et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.
[20] Helmut Baumgartner,et al. ESC / EACTS Guidelines on myocardial revascularization , 2014 .
[21] M. Valgimigli. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY , 2011 .
[22] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[23] G. Dehmer,et al. Drug-eluting coronary artery stents. , 2009, American family physician.
[24] Yi Li,et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. , 2009, JACC. Cardiovascular interventions.
[25] S. Pocock,et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.
[26] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[27] M J Davies,et al. The pathophysiology of acute coronary syndromes , 2000, Heart.